San Diego-based mostly Viking Therapeutics marked itself as a significant competitor while in the weight loss drug marketplace in February soon after revealing promising data from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March